Home › Funds › Cormorant Asset Management, LP › ARWR
Cormorant Asset Management, LP position in ARWR
ARROWHEAD PHARMACEUTICALS IN · Health Care
Cormorant Asset Management, LP reported holding 50,000 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$4.1M, representing 0.21% of its reported portfolio and ranking #41 among its reported holdings. Cormorant Asset Management, LP has disclosed ARWR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's ARWR position evolved
Cormorant Asset Management, LP first disclosed a stake in ARWR in Q1 2026 at 100,000 shares (US$6.3M). Across 2 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 50,000 shares valued at US$4.1M — a reduction of -50,000 shares quarter over quarter.. Notable position changes include a 50% trim in Q2 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 100.00K | $6.27M | New |
| Q2 2026 | 50.00K | $4.08M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 53 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- Avoro Capital Advisors LLC 11.36M sh · $925.59M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 3.30M sh · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M sh · $162.43M · Q2 2026
- Siren, L.L.C. 1.72M sh · $139.83M · Q2 2026
- Vestal Point Capital, LP 1.57M sh · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M sh · $113.22M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.35M sh · $110.08M · Q2 2026
- Hood River Capital Management LLC 1.12M sh · $91.35M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 830.25K sh · $67.67M · Q2 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M sh · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M sh · $27.84M · Q3 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held ARWR?
Cormorant Asset Management, LP has disclosed ARWR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Cormorant Asset Management, LP's current position in ARWR?
As of Q2 2026, Cormorant Asset Management, LP holds 50.00K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $4.08M, representing 0.21% of its reported portfolio and ranking #41.
Has Cormorant Asset Management, LP been buying or selling ARWR?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in ARWR.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.